Design of T-cell receptor libraries with diverse binding properties to examine adoptive T-cell responses

Gene Therapy

Volumn 20, Issue 6, 2013, Pages 634-644

  Chervin, A S ^a   Stone, J D ^a   Soto, C M ^b   Engels, B ^c   Schreiber, H ^c   Roy, E J ^b   Kranz, D M ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adoptive T cell therapy; Affinity engineering; T cell display; TCR; Tumor targeting

Indexed keywords

T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; BIOCHEMISTRY; CANCER CONTROL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; HIGH THROUGHPUT SEQUENCING; IN VITRO STUDY; IN VIVO STUDY; LYMPHOID ORGAN; LYMPHOID TISSUE; MOUSE; NONHUMAN; PEPTIDE LIBRARY; PRIORITY JOURNAL; RECEPTOR BINDING; RNA EXTRACTION; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR INVASION;

ADAPTIVE IMMUNITY; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GENE LIBRARY; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; RECEPTORS, ANTIGEN, T-CELL; RETROVIRIDAE; TISSUE THERAPY; TRANSDUCTION, GENETIC;

MUS;

EID: 84882276058     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.80     Document Type: Article

References (58)

1. Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 2006; 24: 419-466.
2. Garcia KC, Adams JJ, Feng D, Ely LK. The molecular basis of TCR germline bias for MHC is surprisingly simple. Nat Immunol 2009; 10: 143-147.
3. Marrack P, Scott-Browne JP, Dai S, Gapin L, Kappler JW. Evolutionarily conserved amino acids that control TCR-MHC interaction. Annu Rev Immunol 2008; 26: 171-203.
4. Gras S, Kjer-Nielsen L, Burrows SR, McCluskey J, Rossjohn J. T-cell receptor bias and immunity. Curr Opin Immunol 2008; 20: 119-125.
5. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666-675.
6. Gattinoni L, Powell Jr DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006; 6: 383-393.
7. Schmitt TM, Ragnarsson GB, Greenberg PD. T cell receptor gene therapy for cancer. Hum Gene Ther 2009; 20: 1240-1248.
8. Bendle GM, Haanen JB, Schumacher TN. Preclinical development of T cell receptor gene therapy. Curr Opin Immunol 2009; 21: 209-214.
9. Schumacher TN, Restifo NP. Adoptive T cell therapy of cancer. Curr Opin Immunol 2009; 21: 187-189.
10. Schepers K, Swart E, van Heijst JW, Gerlach C, Castrucci M, Sie D et al. Dissecting T cell lineage relationships by cellular barcoding. J Exp Med 2008; 205: 2309-2318.
11. Gerlach C, van Heijst JW, Swart E, Sie D, Armstrong N, Kerkhoven RM et al. One naive T cell, multiple fates in CD8\+ T cell differentiation. J Exp Med 2010; 207: 1235-1246.
12. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129.
13. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114: 535-546.
14. Rosenberg SA. Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Mol Ther 2010; 18: 1744-1745.
15. Chen J, Eisen HN, Kranz DM. A model T-cell receptor system for studying memory T-cell development. Microbes Infect 2003; 5: 233-240.
16. Udaka K, Wiesmuller K, Kienle S, Jung G, Walden P. Self-MHC-restricted peptides recognized by an alloreactive T-lymphocyte clone. J Immunol 1996; 157: 670-678.
17. Holler PD, Chlewicki LK, Kranz DM. TCRs with high affinity for foreign pMHC show self-reactivity. Nat Immunol 2003; 4: 55-62.
18. Chervin AS, Stone JD, Holler PD, Bai A, Chen J, Eisen HN et al. The impact of TCRbinding properties and antigen presentation format on T cell responsiveness. J Immunol 2009; 183: 1166-1178.
19. Manning TC, Schlueter CJ, Brodnicki TC, Parke EA, Speir JA, Garcia KC et al. Alanine scanning mutagenesis of an alphabeta T cell receptor: mapping the energy of antigen recognition. Immunity 1998; 8: 413-425.
20. Lee PU, Churchill HR, Daniels M, Jameson SC, Kranz DM. Role of 2C T cell receptor residues in the binding of self-and allo-major histocompatibility complexes. J Exp Med 2000; 191: 1355-1364.
21. Tallquist MD, Yun TJ, Pease LR. A single T cell receptor recognizes structurally distinct MHC/peptide complexes with high specificity. J Exp Med 1996; 184: 1017-1026.
22. Garcia KC, Tallquist MD, Pease LR, Brunmark A, Scott CA, Degano M et al. Alphabeta T cell receptor interactions with syngeneic and allogeneic ligands: affinity measurements and crystallization. Proc Natl Acad Sci USA 1997; 94: 13838-13843.
23. Garcia KC, Degano M, Stanfield RL, Brunmark A, Jackson MR, Peterson PA et al. An alphabeta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science 1996; 274: 209-219.
24. Santori FR, Kieper WC, Brown SM, Lu Y, Neubert TA, Johnson KL et al. Rare, structurally homologous self-peptides promote thymocyte positive selection. Immunity 2002; 17: 131-142.
25. Holler PD, Kranz DM. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 2003; 18: 255-264.
26. Degano M, Garcia KC, Apostolopoulos V, Rudolph MG, Teyton L, Wilson IA. A functional hot spot for antigen recognition in a superagonist TCR/MHC complex. Immunity 2000; 12: 251-261.
27. Kessels HW, van Den Boom MD, Spits H, Hooijberg E, Schumacher TN. Changing T cell specificity by retroviral T cell receptor display. Proc Natl Acad Sci USA 2000; 97: 14578-14583.
28. Chervin AS, Aggen DH, Raseman JM, Kranz DM. Engineering higher affinity T cell receptors using a T cell display system. J Immunol Methods 2008; 339: 175-184.
29. Engels B, Noessner E, Frankenberger B, Blankenstein T, Schendel DJ, Uckert W. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. Hum Gene Ther 2005; 16: 799-810.
30. Schambach A, Wodrich H, Hildinger M, Bohne J, Krausslich HG, Baum C. Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol Ther 2000; 2: 435-445.
31. Kuball J, Dossett ML, Wolfl M, Ho WY, Voss RH, Fowler C et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 2007; 109: 2331-2338.
32. Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 2007; 67: 3898-3903.
33. Engels B, Chervin AS, Sant AJ, Kranz DM, Schreiber H. Long-term persistence of CD4(\+) but rapid disappearance of CD8(\+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity. Mol Ther 2012; 20: 652-660.
34. Daniels MA, Jameson SC. Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers. J Exp Med 2000; 191: 335-346.
35. Cho BK, Lian KC, Lee P, Brunmark A, McKinley C, Chen J et al. Differences in antigen recognition and cytolytic activity of CD8(\+) and CD8(-) T cells that express the same antigen-specific receptor. Proc Natl Acad Sci USA 2001; 98: 1723-1727.
36. Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med 2004; 10: 294-298.
37. Cheung AF, Dupage MJ, Dong HK, Chen J, Jacks T. Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer Res 2008; 68: 9459-9468.
38. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8\+ T cells. Cancer Res 2004; 64: 1140-1145.
39. Koya RC, Mok S, Comin-Anduix B, Chodon T, Radu CG, Nishimura MI et al. Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc Natl Acad Sci USA 2010; 107: 14286-14291.
40. Thomas DL, Kim M, Bowerman NA, Narayanan S, Kranz DM, Schreiber H et al. Recurrence of intracranial tumors following adoptive T cell therapy can be prevented by direct and indirect killing aided by high levels of tumor antigen crosspresented on stromal cells. J Immunol 2009; 183: 1828-1837.
41. Ge Q, Hu H, Eisen HN, Chen J. Different contributions of thymopoiesis and homeostasis-driven proliferation to the reconstitution of naive and memory T cell compartments. Proc Natl Acad Sci USA 2002; 99: 2989-2994.
42. Surh CD, Sprent J. Homeostasis of naive and memory T cells. Immunity 2008; 29: 848-862.
43. Bowerman NA, Crofts TS, Chlewicki L, Do P, Baker BM, Christopher Garcia K et al. Engineering the binding properties of the T cell receptor:peptide:MHC ternary complex that governs T cell activity. Mol Immunol 2009; 46: 3000-3008.
44. Corse E, Gottschalk RA, Krogsgaard M, Allison JP. Attenuated T cell responses to a high-potency ligand in vivo. PLoS Biol 2010; 8: pii: e1000481.
45. Ghani S, Feuerer M, Doebis C, Lauer U, Loddenkemper C, Huehn J et al. T cells as pioneers: antigen-specific T cells condition inflamed sites for high-rate antigennon-specific effector cell recruitment. Immunology 2009; 128: e870-e880.
46. Palmer DC, Balasubramaniam S, Hanada K, Wrzesinski C, Yu Z, Farid S et al. Vaccine-stimulated, adoptively transferred CD8\+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol 2004; 173: 7209-7216.
47. Charo J, Perez C, Buschow C, Jukica A, Czeh M, Blankenstein T. Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors. Eur J Immunol 2011; 41: 3187-3197.
48. Scott-Browne JP, White J, Kappler JW, Gapin L, Marrack P. Germline-encoded amino acids in the alphabeta T-cell receptor control thymic selection. Nature 2009; 458: 1043-1046.
49. Stemberger C, Huster KM, Koffler M, Anderl F, Schiemann M, Wagner H et al. A single naive CD8\+ T cell precursor can develop into diverse effector and memory subsets. Immunity 2007; 27: 985-997.
50. Gottschalk RA, Corse E, Allison JP. TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. J Exp Med 2010; 207: 1701-1711.
51. Li Y, Moysey R, Molloy PE, Vuidepot AL, Mahon T, Baston E et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol 2005; 23: 349-354.
52. Aggen DH, Chervin AS, Insaidoo FK, Piepenbrink KH, Baker BM, Kranz DM. Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors. Protein Eng Des Sel 2011; 24: 361-372.
53. Li LP, Lampert JC, Chen X, Leitao C, Popovic J, Muller W et al. Transgenic mice with a diverse human T cell antigen receptor repertoire. Nat Med 2010; 16: 1029-1034.
54. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibodybinding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993; 90: 720-724.
55. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-733.
56. Engels B, Cam H, Schuler T, Indraccolo S, Gladow M, Baum C et al. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther 2003; 14: 1155-1168.
57. Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Therapy 2000; 7: 1063-1066.
58. Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF et al. Increasing tumor antigen expression overcomes 'ignorance' to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002; 17: 737-747.